L-DOPA- and graft-induced dyskinesia following transplantation

Progress in Brain Research

Volumn 200, Issue , 2012, Pages 143-168

  Lane, Emma L ^a   Winkler, Christian ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Abnormal involuntary movements; Amphetamine; Dopamine; Dyskinesia; L DOPA; Serotonin; Transplantation

Indexed keywords

ALPHA SYNUCLEIN; AMANTADINE; AMPHETAMINE; ANTIPARKINSON AGENT; APOMORPHINE; BUSPIRONE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LEVODOPA; SEROTONIN; TRANSCRIPTION FACTOR FOSB;

AKINESIA; ARTICLE; BASAL GANGLION; BRADYKINESIA; BRAIN DEPTH STIMULATION; CATECHOLAMINE NERVE CELL; CELL SURVIVAL; CELL SUSPENSION; CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINE RELEASE; DYSKINESIA; ELECTROPHYSIOLOGY; GRAFT FAILURE; GRAFT INDUCED DYSKINESIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNERVATION; INVOLUNTARY MOVEMENT; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATIENT SELECTION; PRACTICE GUIDELINE; PREGNANCY TERMINATION; PRIORITY JOURNAL; RIGIDITY; SEROTONINERGIC SYSTEM; SUBSTANTIA NIGRA;

EID: 84870264303     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-59575-1.00007-7     Document Type: Chapter

References (106)

1. Adams C.E., Hoffman A.F., Hudson J.L., Hoffer B.J., Boyson S.J. Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats. Exp. Neurol. 1994, 130:261-268.
2. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 2001, 16:448-458.
3. Alexander T., Sortwell C.E., Sladek C.D., Roth R.H., Steece-Collier K. Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors. Cell Transplant. 1997, 6:309-315.
4. Andersson M., Hilbertson A., Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6:461-474.
5. Astradsson A., Jenkins B.G., Choi J.K., Hallett P.J., Levesque M.A., McDowell J.S., Brownell A.L., Spealman R.D., Isacson O. The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates-evidence from in vivo neuroimaging studies. Neurobiol. Dis. 2009, 35:348-351.
6. Backlund E.O., Granberg P.O., Hamberger B., Knutsson E., Martensson A., Sedvall G., Seiger A., Olson L. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg. 1985, 62:169-173.
7. Bedard P.J., Di Paolo T., Falardeau P., Boucher R. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res. 1986, 379:294-299.
8. Björklund A., Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 1979, 177:555-560.
9. Björklund A., Dunnett S.B., Stenevi U., Lewis M.E., Iversen S.D. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 1980, 199:307-333.
10. Björklund A., Stenevi U., Dunnett S.B., Iversen S.D. Functional reactivation of the deafferented neostriatum by nigral transplants. Nature 1981, 289:497-499.
11. Björklund A., Stenevi U., Dunnett S.B., Gage F.H. Cross-species neural grafting in a rat model of Parkinson's disease. Nature 1982, 298:652-654.
12. Brundin P., Strecker R.E., Clarke D.J., Widner H., Nilsson O.G., Astedt B., Lindvall O., Björklund A. Can human fetal dopamine neuron grafts provide a therapy for Parkinson's disease?. Prog. Brain Res. 1988, 78:441-448.
13. Brundin P., Widner H., Nilsson O.G., Strecker R.E., Björklund A. Intracerebral xenografts of dopamine neurons: the role of immunosuppression and the blood-brain barrier. Exp. Brain Res. 1989, 75:195-207.
14. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., Kupsch A., Crabb L., Odin P., Gustavii B., Björklund A., Brooks D.J., Marsden C.D., Oertel W.H., Quinn N.P., Rehncrona S., Lindvall O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000, 123(Pt. 7):1380-1390.
15. Carlsson T., Winkler C., Lundblad M., Cenci M.A., Björklund A., Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol. Dis. 2006, 21:657-668.
16. Carlsson T., Carta M., Winkler C., Björklund A., Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 2007, 27:8011-8022.
17. Carlsson T., Carta M., Munoz A., Mattsson B., Winkler C., Kirik D., Björklund A. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009, 132:319-335.
18. Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
19. Carta M., Carlsson T., Munoz A., Kirik D., Björklund A. Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S154-S158.
20. Carta M., Carlsson T., Munoz A., Kirik D., Björklund A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog. Brain Res. 2008, 172:465-478.
21. Cenci M.A., Campbell K., Björklund A. Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels. Neuroscience 1993, 57:275-296.
22. Cenci M.A., Whishaw I.Q., Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat. Rev. Neurosci. 2002, 3:574-579.
23. Cho C., Alterman R., Miravite J., Shils J., Taglati M. Subthalamic DBS for the treatment of 'runaway' dyskinesias after embryonic or fetal tissue transplant. Mov. Disord. 2005, 20:1237.
24. Chritin M., Savasta M., Mennicken F., Bal A., Abrous D.N., Le Moal M., Feuerstein C., Herman J.P. Intrastriatal dopamine-rich implants reverse the increase of dopamine D2 receptor mRNA levels caused by lesion of the nigrostriatal pathway: a quantitative in situ hybridization study. Eur. J. Neurosci. 1992, 4:663-672.
25. Cochen V., Ribeiro M.J., Nguyen J.P., Gurruchaga J.M., Villafane G., Loc'h C., Defer G., Samson Y., Peschanski M., Hantraye P., Cesaro P., Remy P. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Mov. Disord. 2003, 18:928-932.
26. Cragg S.J., Rice M.E. DAncing past the DAT at a DA synapse. Trends Neurosci. 2004, 27:270-277.
27. Datla K.P., Blunt S.B., Dexter D.T. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov. Disord. 2001, 16:424-434.
28. Defer G.L., Geny C., Ricolfi F., Fenelon G., Monfort J.C., Remy P., Villafane G., Jeny R., Samson Y., Keravel Y., Gaston A., Degos J.D., Peschanski M., Cesaro P., Nguyen J.P. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 1996, 119(Pt. 1):41-50.
29. de la Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., Ruth T.J., Stoessl A.J. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
30. Fox S.H., Henry B., Hill M.P., Peggs D., Crossman A.R., Brotchie J.M. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov. Disord. 2001, 16:642-650.
31. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Wells T.H., Barrett J.N., Grafton S.T., Huang S.C., Eidelberg D., Rottenberg D.A. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. Arch. Neurol. 1990, 47:505-512.
32. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., Lone T., Zhang Y.B., Snyder J.A., Wells T.H., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Engl. J. Med. 1992, 327:1549-1555.
33. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
34. Freed C., Breeze R., Fahn S., Eidelberg D. Preoperative response to levodopa in the best predictor of transplant outcome. Ann. Neurol. 2004, 55:896-897.
35. Garcia J., Carlsson T., Dobrossy M., Nikkhah G., Winkler C. Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation. Exp. Neurol. 2011, 232:270-279.
36. Garcia J., Carlsson T., Dobrossy M., Nikkhah G., Winkler C. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiol. Dis. 2011, 43:576-587.
37. Garcia J., Carlsson T., Dobrossy M., Nikkhah G., Winkler C. Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinsonian model. Brain Res. 2012, 1470:119-129.
38. Grealish S., Jonsson M.E., Li M., Kirik D., Björklund A., Thompson L.H. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain 2010, 133:482-495.
39. Greene P., Fahn S., Tsai W.Y., Breeze R., Eidelberg D., Winfield H., Dillon S., Kao R., Winfield L., Freed C. Severe spontaneous dyskinesias: a disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease. Mov. Disord. 1999, 14:904.
40. Guigoni C., Aubert I., Li Q., Gurevich V.V., Benovic J.L., Ferry S., Mach U., Stark H., Leriche L., Hakansson K., Bioulac B.H., Gross C.E., Sokoloff P., Fisone G., Gurevich E.V., Bloch B., Bezard E. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S25-S29.
41. Hagell P., Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J. Neuropathol. Exp. Neurol. 2001, 60:741-752.
42. Hagell P., Cenci M.A. Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res. Bull. 2005, 68:4-15.
43. Hagell P., Schrag A., Piccini P., Jahanshahi M., Brown R., Rehncrona S., Widner H., Brundin P., Rothwell J.C., Odin P., Wenning G.K., Morrish P., Gustavii B., Björklund A., Brooks D.J., Marsden C.D., Quinn N.P., Lindvall O. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 1999, 122(Pt. 6):1121-1132.
44. Hagell P., Piccini P., Björklund A., Brundin P., Rehncrona S., Widner H., Crabb L., Pavese N., Oertel W.H., Quinn N., Brooks D.J., Lindvall O. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 2002, 5:627-628.
45. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., Olanow C.W. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 1999, 56:179-187.
46. Herrera-Marschitz M., Strömberg I., Olsson D., Ungerstedt U., Olson L. Adrenal medullary implants in the dopamine-denervated rat striatum. II. Acute behavior as a function of graft amount and location and its modulation by neuroleptics. Brain Res. 1984, 297:53-61.
47. Herzog J., Pogarell O., Pinsker M.O., Kupsch A., Oertel W.H., Lindvall O., Deuschl G., Volkmann J. Deep brain stimulation in Parkinson's disease following fetal nigral transplantation. Mov. Disord. 2008, 23:1293-1296.
48. Ishida Y., Kuwahara I., Todaka K., Hashiguchi H., Nishimori T., Mitsuyama Y. Dopaminergic transplants suppress L-DOPA-induced Fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. Brain Res. 1996, 727:205-211.
49. Jacques D.B., Kopyov O.V., Eagle K.S., Carter T., Lieberman A. Outcomes and complications of fetal tissue transplantation in Parkinson's disease. Stereotact. Funct. Neurosurg. 1999, 72:219-224.
50. Jenner P. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann. Neurol. 2008, 64(Suppl. 2):S16-S29.
51. Kopyov O.V., Jacques D.S., Lieberman A., Duma C.M., Rogers R.L. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Exp. Neurol. 1997, 146:536-545.
52. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
53. Kordower J.H., Chu Y., Hauser R.A., Olanow C.W., Freeman T.B. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov. Disord. 2008, 23:2303-2306.
54. Kumar N., Van Gerpen J.A., Bower J.H., Ahlskog J.E. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov. Disord. 2005, 20:342-344.
55. Lane E.L., Smith G.A. Understanding graft-induced dyskinesia. Regen. Med. 2010, 5:787-797.
56. Lane E.L., Winkler C., Brundin P., Cenci M.A. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol. Dis. 2006, 22:334-345.
57. Lane E.L., Soulet D., Vercammen L., Cenci M.A., Brundin P. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiol. Dis. 2008, 32:9.
58. Lane E.L., Brundin P., Cenci M.A. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiol. Dis. 2009, 35:42-51.
59. Lane E.L., Vercammen L., Cenci M.A., Brundin P. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Exp. Neurol. 2009, 219:355-358.
60. Lane E.L., Björklund A., Dunnett S., Winkler C. Neural grafting in Parkinson's disease: unraveling the mechanisms underlying graft-induced dyskinesia. Prog. Brain Res. 2010, 184:295-309.
61. Lee C.S., Cenci M.A., Schulzer M., Björklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000, 123(Pt. 7):1365-1379.
62. Levivier M., Dethy S., Rodesch F., Peschanski M., Vandesteene A., David P., Wikler D., Goldman S., Claes T., Biver F., Liesnard C., Goldman M., Hildebrand J., Brotchi J. Intracerebral transplantation of fetal ventral mesencephalon for patients with advanced Parkinson's disease. Methodology and 6-month to 1-year follow-up in 3 patients. Stereotact. Funct. Neurosurg. 1997, 69:99-111.
63. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., Lashley T., Quinn N.P., Rehncrona S., Björklund A., Widner H., Revesz T., Lindvall O., Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
64. Lindgren H.S., Rylander D., Iderberg H., Andersen M.L., O'Sullivan S.S., Williams D.R., Lees A., Cenci A. Putaminal upregulation of FosB-like immunoreactivity in Parkinson's disease patients with dyskinesia. J. Parkinson's Dis. 2011, 1:347-357.
65. Lindvall O. Update on fetal transplantation: the Swedish experience. Mov. Disord. 1998, 13(Suppl. 1):83-87.
66. Lindvall O., Björklund A. Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials. Acta Neurol. Scand. Suppl. 1989, 126:197-210.
67. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., Breeze R., Fahn S., Freed C., Eidelberg D. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol. 2002, 52:628-634.
68. Ma Y., Tang C., Chaly T., Greene P., Breeze R., Fahn S., Freed C., Dhawan V., Eidelberg D. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J. Nucl. Med. 2010, 51:7-15.
69. Machado-Salas J., Cornejo A., Ibarra O., Aceves J., Martinez Fong D., Huerta G., Kuri J. Multidisciplinary analysis of the effectiveness of autologous neural transplant (adrenal medulla) as treatment of Parkinson's disease. Stereotact. Funct. Neurosurg. 1990, 54-55:306-311.
70. Maries E., Collier T.J., Olaru E., Sortwell C.E., Shannon K.M., Kordower J.H., Steece-Collier K. Correlation of graft-derived reinnervation with post-graft dyskinesia occurrence in a rat model of Parkinson's disease 2003.
71. Mendez I., Dagher A., Hong M., Hebb A., Gaudet P., Law A., Weerasinghe S., King D., Desrosiers J., Darvesh S., Acorn T., Robertson H. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J. Neurosurg. 2000, 92:863-869.
72. Mendez I., Sanchez-Pernaute R., Cooper O., Vinuela A., Ferrari D., Björklund L., Dagher A., Isacson O. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005, 128:1498-1510.
73. Mendez I., Vinuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., Tierney T., Holness R., Dagher A., Trojanowski J.Q., Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 2008, 14:507-509.
74. Monahan A.J., Warren M., Carvey P.M. Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant. 2008, 17:363-372.
75. Mouradian M.M., Juncos J.L., Fabbrini G., Schlegel J., Bartko J.J., Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann. Neurol. 1988, 24:372-378.
76. Nadaud D., Herman J.P., Simon H., Le Moal M. Functional recovery following transplantation of ventral mesencephalic cells in rat subjected to 6-OHDA lesions of the mesolimbic dopaminergic neurons. Brain Res. 1984, 304:137-141.
77. Oertel W.H., Wolters E., Sampaio C., Gimenez-Roldan S., Bergamasco B., Dujardin M., Grosset D.G., Arnold G., Leenders K.L., Hundemer H.P., Lledo A., Wood A., Frewer P., Schwarz J. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov. Disord. 2006, 21:343-353.
78. Ohlin K.E., Sebastianutto I., Adkins C.E., Lundblad C., Lockman P.R., Cenci M.A. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. Neuroimage 2012, 61:228-239.
79. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
80. Olanow C.W., Gracies J.M., Goetz C.G., Stoessl A.J., Freeman T., Kordower J.H., Godbold J., Obeso J.A. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov. Disord. 2009, 24:336-343.
81. Perlow M.J., Freed W.J., Hoffer B.J., Seiger A., Olson L., Wyatt R.J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979, 204:643-647.
82. Peschanski M., Defer G., N'Guyen J.P., Ricolfi F., Monfort J.C., Remy P., Geny C., Samson Y., Hantraye P., Jeny R., et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994, 117(Pt. 3):487-499.
83. Piccini P., Pavese N., Hagell P., Reimer J., Björklund A., Oertel W.H., Quinn N.P., Brooks D.J., Lindvall O. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005, 128:2977-2986.
84. Pogarell O., Koch W., Gildehaus F.J., Kupsch A., Lindvall O., Oertel W.H., Tatsch K. Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:407-411.
85. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., Bjorklund A., Lindvall O., Piccini P. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2010, 2:38ra46.
86. Politis M., Oertel W.H., Wu K., Quinn N.P., Pogarell O., Brooks D.J., Björklund A., Lindvall O., Piccini P. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov. Disord. 2011, 26:1997-2003.
87. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E., Abdalla M. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov. Disord. 2006, 21:1844-1850.
88. Ravenstijn P.G., Drenth H.J., O'Neill M.J., Danhof M., de Lange E.C. Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease. Fluids Barriers CNS 2012, 9:4.
89. Redmond D.E., Vinuela A., Kordower J.H., Isacson O. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol. Dis. 2008, 29:103-116.
90. Rinne U.K., Rinne J.O., Rinne J.K., Laakso K., Laihinen A., Lonnberg P. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment. J. Neural Transm. Suppl. 1983, 18:279-286.
91. Rioux L., Gagnon C., Gaudin D.P., Di Paolo T., Bedard P.J. A fetal nigral graft prevents behavioral supersensitivity associated with repeated injections of L-dopa in 6-OHDA rats. Correlation with D1 and D2 receptors. Neuroscience 1993, 56:45-51.
92. Savasta M., Mennicken F., Chritin M., Abrous D.N., Feuerstein C., Le Moal M., Herman J.P. Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats: an autoradiographic study. Neuroscience 1992, 46:729-738.
93. Shin E., Garcia J., Winkler C., Björklund A., Carta M. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease. Neurobiol. Dis. 2012, 47:393-406.
94. Smith G.A., Dunnett S.B., Lane E.L. Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats. Neuropharmacology 2012, 63:818-828.
95. Smith G.A., Heuer A., Klein A., Vinh N., Dunnett S.B., Lane E.L. Amphetamine-induced dyskinesia in the transplanted hemi-parkinsonian mouse. J. Parkinson's Dis. 2012, 2:107-113.
96. Soderstrom K.E., Meredith G., Freeman T.B., McGuire S.O., Collier T.J., Sortwell C.E., Wu Q., Steece-Collier K. The synaptic impact of the host immune response in a parkinsonian allograft rat model: influence on graft-derived aberrant behaviors. Neurobiol. Dis. 2008, 32:14.
97. Steece-Collier K., Soderstrom K.E., Collier T.J., Sortwell C.E., Maries-Lad E. Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. J. Comp. Neurol. 2009, 515:15-30.
98. Strömberg I., Herrera-Marschitz M., Hultgren L., Ungerstedt U., Olson L. Adrenal medullary implants in the dopamine-denervated rat striatum. I. Acute catecholamine levels in grafts and host caudate as determined by HPLC-electrochemistry and fluorescence histochemical image analysis. Brain Res. 1984, 297:41-51.
99. Tekumalla P.K., Calon F., Rahman Z., Birdi S., Rajput A.H., Hornykiewicz O., Di Paolo T., Bedard P.J., Nestler E.J. Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol. Psychiatry 2001, 50:813-816.
100. Thompson L., Barraud P., Andersson E., Kirik D., Bjorklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J. Neurosci. 2005, 25:6467-6477.
101. Turjanski N., Lees A.J., Brooks D.J. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997, 49:717-723.
102. Vinuela A., Hallett P.J., Reske-Nielsen C., Patterson M., Sotnikova T.D., Caron M.G., Gainetdinov R.R., Isacson O. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain 2008, 131:3361-3379.
103. Westin J.E., Lindgren H.S., Gardi J., Nyengaard J.R., Brundin P., Mohapel P., Cenci M.A. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J. Neurosci. 2006, 26:9448-9461.
104. Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P., Gustavii B., Bjorklund A., Lindvall O., Langston J.W. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 1992, 327:1556-1563.
105. Winkler C., Kirik D., Björklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
106. Winkler C., Bentlage C., Cenci M.A., Nikkhah G., Bjorklund A. Regulation of neuropeptide mRNA expression in the basal ganglia by intrastriatal and intranigral transplants in the rat Parkinson model. Neuroscience 2003, 118:1063-1077.